CNXC

SEC source: 0001803599-21-000087 · wf-form4_161912874563255.xml · nonDerivative · entry 1

Marinello Kathryn V · CIK 0001378931 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the earlier of (x) the one-year anniversary of the date of grant and (y) the date of the Issuer's 2022 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000085 · wf-form4_161912869275483.xml · nonDerivative · entry 1

Deason Jennifer · CIK 0001679060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the earlier of (x) the one-year anniversary of the date of grant and (y) the date of the Issuer's 2022 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000084 · wf-form4_161912866646133.xml · nonDerivative · entry 1

Council LaVerne H · CIK 0001788616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the earlier of (x) the one-year anniversary of the date of grant and (y) the date of the Issuer's 2022 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000083 · wf-form4_161912864034896.xml · nonDerivative · entry 1

Chou Teh-Chien · CIK 0001834419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,118

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the earlier of (x) the one-year anniversary of the date of grant and (y) the date of the Issuer's 2022 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000065 · wf-form4_161722595971887.xml · nonDerivative · entry 1

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,272

SEC source: 0001803599-21-000038 · wf-form4_161222264111831.xml · nonDerivative · entry 2

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,718

SEC source: 0001803599-21-000038 · wf-form4_161222264111831.xml · nonDerivative · entry 1

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,715

F1 · kind: Represents shares issued upon the vesting of restricted stock units awarded on February 14, 2018 subject to the satisfaction of performance metrics measured over a three-year period ending November 30, 2020.

SEC source: 0001803599-21-000033 · wf-form4_161135423302383.xml · nonDerivative · entry 2

Rosso Richard · CIK 0001832714 · EVP, Global Sales & Acct. Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,953

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.45 to $119.50, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001803599-21-000034 · wf-form4_161135424916294.xml · nonDerivative · entry 1

Twomey Cormac J · CIK 0001722281 · EVP, Global Ops & Delivery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,412

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 25% of the shares on each of the first four anniversaries of October 7, 2020.

SEC source: 0001803599-21-000025 · wf-form4_161135408559847.xml · derivative · entry 3

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,212

Underlying: Common Stock · 26,212 shares

Expires 2031-01-20

F3 · derivative.exercise_date: This stock option vests as to 20% of the shares on the first anniversary of October 7, 2020 and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-21-000025 · wf-form4_161135408559847.xml · nonDerivative · entry 2

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,068

F2 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 20% of the shares on each of the first five anniversaries of October 7, 2020.

SEC source: 0001803599-21-000025 · wf-form4_161135408559847.xml · nonDerivative · entry 1

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,474

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 20% of the shares on each of the first five anniversaries of December 1, 2020.

SEC source: 0001803599-21-000035 · wf-form4_161135426532175.xml · nonDerivative · entry 1

Valentine Andre S · CIK 0001477299 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,253

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 25% of the shares on each of the first four anniversaries of October 7, 2020.

SEC source: 0001803599-21-000029 · wf-form4_161135415989705.xml · nonDerivative · entry 1

Hayley Kathryn · CIK 0001431838 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000036 · wf-form4_161135428220411.xml · nonDerivative · entry 1

VEZINA ANN F · CIK 0001356299 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,703

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000031 · wf-form4_161135419690754.xml · nonDerivative · entry 1

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,272

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000030 · wf-form4_161135417763214.xml · nonDerivative · entry 1

Marinello Kathryn V · CIK 0001378931 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000028 · wf-form4_161135413829510.xml · nonDerivative · entry 1

Deason Jennifer · CIK 0001679060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000027 · wf-form4_161135412222630.xml · nonDerivative · entry 1

Council LaVerne H · CIK 0001788616 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000033 · wf-form4_161135423302383.xml · nonDerivative · entry 1

Rosso Richard · CIK 0001832714 · EVP, Global Sales & Acct. Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,453

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 25% of the shares on each of the first four anniversaries of October 7, 2020.

SEC source: 0001803599-21-000032 · wf-form4_161135421636485.xml · nonDerivative · entry 1

Richie Steven L · CIK 0001831653 · EVP, Legal

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,843

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests as to 25% of the shares on each of the first four anniversaries of October 7, 2020.

SEC source: 0001803599-21-000026 · wf-form4_161135410339270.xml · nonDerivative · entry 1

Chou Teh-Chien · CIK 0001834419 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306

F1 · kind: Represents shares of restricted stock awarded under the 2020 Stock Incentive Plan. The restricted stock vests in full on the date of the Issuer's 2021 Annual Meeting of Stockholders.

SEC source: 0001803599-21-000008 · wf-form4_161075128563698.xml · nonDerivative · entry 1

VEZINA ANN F · CIK 0001356299 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,397

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.50 to $119.73, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001803599-20-000035 · wf-form4_160694820149008.xml · nonDerivative · entry 2

SYNNEX CORP · CIK 0001177394 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX, on December 1, 2020, SYNNEX distributed 100% of the outstanding shares of common stock, $0.0001 par value, of Concentrix to the holders of record of SYNNEX common stock as of the close of business on November 17, 2020, the record date for the distribution.

SEC source: 0001803599-20-000054 · wf-form4_160703917537279.xml · nonDerivative · entry 1

Twomey Cormac J · CIK 0001722281 · EVP, Global Ops & Delivery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,707

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 7

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,057

Underlying: Common Stock · 30,057 shares

Expires 2029-10-02

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F6 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 6

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,808

Underlying: Common Stock · 45,808 shares

Expires 2028-10-11

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F5 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 5

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,172

Underlying: Common Stock · 11,172 shares

Expires 2027-10-03

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F4 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 4

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,630

Underlying: Common Stock · 12,630 shares

Expires 2026-10-04

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F3 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 3

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,363

Underlying: Common Stock · 9,363 shares

Expires 2025-10-06

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · derivative · entry 2

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,928

Underlying: Common Stock · 12,928 shares

Expires 2024-10-07

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

SEC source: 0001803599-20-000050 · wf-form4_160703909794350.xml · nonDerivative · entry 1

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,946

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000055 · wf-form4_160703919212322.xml · nonDerivative · entry 1

Valentine Andre S · CIK 0001477299 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,548

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000056 · wf-form4_160703921012132.xml · nonDerivative · entry 1

VEZINA ANN F · CIK 0001356299 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,077

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 9

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,588

Underlying: Common Stock · 46,588 shares

Expires 2029-10-02

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F7 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 8

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,003

Underlying: Common Stock · 71,003 shares

Expires 2028-10-11

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F6 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 7

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,851

Underlying: Common Stock · 37,851 shares

Expires 2028-04-09

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F5 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018 and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 6

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,188

Underlying: Common Stock · 12,188 shares

Expires 2027-10-03

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F4 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 5

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,778

Underlying: Common Stock · 13,778 shares

Expires 2026-10-04

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F3 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 4

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,235

Underlying: Common Stock · 11,235 shares

Expires 2025-10-06

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 3

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,514

Underlying: Common Stock · 15,514 shares

Expires 2024-10-07

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · derivative · entry 2

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,584

Underlying: Common Stock · 10,584 shares

Expires 2023-10-03

F2 · derivative.exercise_price: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

F2 · kind: In connection with the spin-off of Concentrix by SYNNEX and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNNEX stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.

SEC source: 0001803599-20-000051 · wf-form4_160703912154098.xml · nonDerivative · entry 1

POLK DENNIS · CIK 0001270710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,966

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000053 · wf-form4_160703915903130.xml · nonDerivative · entry 1

Rosso Richard · CIK 0001832714 · EVP, Global Sales & Acct. Mgmt

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,748

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000052 · wf-form4_160703914111324.xml · nonDerivative · entry 1

Richie Steven L · CIK 0001831653 · EVP, Legal

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,226

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX"), on December 1, 2020, SYNNEX distributed all of the issued and outstanding shares of Concentrix common stock to SYNNEX stockholders (the "Distribution"). SYNNEX stockholders received one share of Concentrix common stock for each share of SYNNEX common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.

SEC source: 0001803599-20-000059 · wf-form4a_160738770908800.xml · derivative · entry 6

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,057

Underlying: Common Stock · 30,057 shares

Expires 2029-10-02

F1 · derivative.exercise_price: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F5 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000059 · wf-form4a_160738770908800.xml · derivative · entry 5

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,808

Underlying: Common Stock · 45,808 shares

Expires 2028-10-11

F1 · derivative.exercise_price: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F4 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000059 · wf-form4a_160738770908800.xml · derivative · entry 4

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,172

Underlying: Common Stock · 11,172 shares

Expires 2027-10-03

F1 · derivative.exercise_price: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F3 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000059 · wf-form4a_160738770908800.xml · derivative · entry 3

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,630

Underlying: Common Stock · 12,630 shares

Expires 2026-10-04

F1 · derivative.exercise_price: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F2 · derivative.exercise_date: The converted Concentrix stock option has the same vesting schedule as the original SYNNEX stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.

SEC source: 0001803599-20-000059 · wf-form4a_160738770908800.xml · derivative · entry 2

Caldwell Christopher A · CIK 0001604279 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,363

Underlying: Common Stock · 9,363 shares

Expires 2025-10-06

F1 · derivative.exercise_price: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.

F1 · kind: In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNNEX Corporation ("SYNNEX") and pursuant to the employee matters agreement between SYNNEX and Concentrix, on December 1, 2020, each outstanding option to purchase SYNNEX common stock was converted into a stock option to purchase SYNNEX common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNNEX stock option. The exercise price of the converted Concentrix stock option was determined on December 4, 2020 in accordance with the terms of the employee matters agreement. This Form 4/A is being filed to report the adjusted exercise price.